ReviewFrontiers in immunology2026
Ferroptosis and Alzheimer's disease: a new insight into neurodegeneration.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functional Pathological Features and Molecular Markers in Alzheimer's Disease.International journal of molecular sciences · 2026Review
- Metabolic cell death networks in Alzheimer's disease: mechanistic links and therapeutic perspectives of ferroptosis, cuproptosis, and disulfidptosis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), a chronic and progressive neurodegenerative disorder, poses a significant threat to the health of the aging population. The pathological hallmarks of AD include the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs) within the brain. While substantial neuronal loss has been consistently observed in AD, the precise mechanisms underlying neuronal elimination remain incompletely understood. As a distinct form of regulated cell death, the contribution of ferroptosis to AD pathogenesis and progression warrants further investigation. This review critically examines the amyloid cascade hypothesis within the context of AD, with particular emphasis on the molecular signatures of ferroptosis and their contributions to canonical AD pathogenesis and cognitive decline. We aim to provide an updated perspective on AD etiopathogenesis. Furthermore, we synthesize current therapeutic strategies targeting ferroptosis inhibition in AD, highlighting recent advances that hold significant implications for guiding present and future translational efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.